Chester County News and Community Website
SAN DIEGO, CA and PHILADELPHIA, PA — BioAtla, Inc. and Context Therapeutics Inc. have entered into a significant agreement, granting Context an exclusive, worldwide license to develop and commercialize BioAtla’s BA3362, …
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated this week unveiled interim results from its Phase 1 trial of PRT3789, a pioneering therapy designed to target cancers with a SMARCA4 mutation. The data, …
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment Read More
BERWYN, PA — Panavance Therapeutics Inc. has announced the publication of encouraging data on misetionamide in the peer-reviewed journal, Cancer Medicine. The study conducted by Kim et al. at MD …
Panavance Therapeutics Reports Positive Data on Misetionamide in Ovarian Cancer Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced a significant addition to its drug pipeline with the acquisition of CT-95 from Link Immunotherapeutics, Inc. The asset is a mesothelin …
Context Therapeutics Acquires Promising Cancer Treatment Asset Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has announced a collaboration with Merck to evaluate a new cancer treatment. The Phase 2 clinical trial will test Prelude’s investigational drug, …
Prelude Therapeutics Joins Forces with Merck for Cancer Treatment Trial Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) has announced that the national supply of cisplatin, a key cancer medication, now exceeds demand, ending a critical shortage that began …
FDA Announces End to National Shortage of Crucial Cancer Drug Cisplatin Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval to Epkinly (epcoritamab-bysp), a new treatment option for adults with relapsed or refractory follicular lymphoma (FL). This …
FDA Grants Accelerated Approval to New Treatment for Relapsed Follicular Lymphoma Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) has released new survey results highlighting persistent drug shortages in cancer treatment across the United States. While the availability of …
NCCN Survey Reveals Ongoing Cancer Drug Shortages Despite Improvements Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its innovative cancer treatment, CT-0525. This therapy targets …
FDA Grants Fast Track Status to Carisma Therapeutics’ New Cancer Therapy Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will host a virtual Key Opinion Leader (KOL) event on June 24, 2024, at 9:00 AM ET to discuss APR-1051, their highly …
Aprea Therapeutics Hosts Virtual Event on Promising Cancer Therapy Read More